LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A10224615" target="_blank" >RIV/61989592:15110/11:10224615 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Popis výsledku v původním jazyce

LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of apoB and various amounts of cholesterol, apoB is a bettermarker of atherogenic particle numbers. Many laboratory, prospective and interventional studies have proved that apoB is a better indicator of cardiovascular risk than LDL-C. Statins lower LDL-C and non-HDL-C more (and to lower population percentile levels) than apoB. As a result, many patients treated with statins to achieve LDL-C and non-HDL-C targets remain at high risk owing to high levels of apoB, especially subjects with the prevalence of small dense LDL. With the worldwide increasing prevalenceof obesity and metabolic syndrome, the issue of appropriate risk markers and treatment goals is even more important.

Název v anglickém jazyce

LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?

Popis výsledku anglicky

LDL-C is considered to be the major lipid risk factor and the main target of lipid-lowering therapy. Nevertheless, as all potentially atherogenic lipoprotein particles contain only one molecule of apoB and various amounts of cholesterol, apoB is a bettermarker of atherogenic particle numbers. Many laboratory, prospective and interventional studies have proved that apoB is a better indicator of cardiovascular risk than LDL-C. Statins lower LDL-C and non-HDL-C more (and to lower population percentile levels) than apoB. As a result, many patients treated with statins to achieve LDL-C and non-HDL-C targets remain at high risk owing to high levels of apoB, especially subjects with the prevalence of small dense LDL. With the worldwide increasing prevalenceof obesity and metabolic syndrome, the issue of appropriate risk markers and treatment goals is even more important.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

<a href="/cs/project/NS10284" target="_blank" >NS10284: Dyslipidémie a prehypertenze - asociace dyslipidemických fenotypů s výskytem prehypertenze. Asociace prehypertenze s markery inzulínové rezistence, zánětu, endoteliálni dysfunkce, trombózy a subklinické aterosklerózy.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lipidology

ISSN

1758-4299

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

35-48

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—